Sarepta Therapeutics, Inc. - Common Stock (SRPT)

U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower in premarket.

Markets rebound on hopes of Iran de-escalation; oil drops, Roku surges on Amazon deal, Fed decision looms.

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a second death linked to its Duchenne muscular dystrophy gene therapy,. Elevidys, after a patient succumbed to acute liver failure. 

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Piper Sandler cut its Elevidys peak sales estimate to $1.7 billion from $2.4 billion.

The company is working with an independent group to determine if there's a better immunosuppressive regimen.

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

While Dow Jones futures gained 0.41% at the time of writing, the S&P 500 futures rose 0.48%.

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

BMO Capital downgraded the stock, warning of rising regulatory uncertainty and potential revenue impact.

RegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch.

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.